Navigation Links
Randomized Controlled Clinical Trial Shows Derma Sciences MEDIHONEY(TM) Eradicates MRSA From Chronic Venous Ulcers
Date:6/17/2008

the three. A recent market research report by Kalorama Information details the emergence of honey-based dressings as a growing sub-category within active dressings.

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound-care products. Its key product, MEDIHONEY, is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of a large-scale randomized controlled trial on leg ulcers. Derma has two products in development: the NIMBUS technology based line of barrier gauze dressings, and DSC127, the company's novel angiotensin analog for accelerated wound healing and scar reduction. The barrier technology was licensed from Quick-Med in Q1 of 2007 and is pending its initial FDA marketing clearance. DSC127 was licensed from The University of Southern California in Q4 of 2007 and is entering into a Phase II study, with anticipated initial patient enrollment to begin in Q3 of 2008. For more information about Derma Sciences, Inc., visit its home page on the Internet at http://www.dermasciences.com.

About the Journal of Wound Care (JWC)

JWC is the definitive wound-care journal and the leading source of tissue viability research and clinical information. Launched in 1992, it is designed to meet the needs of the multidisciplinary team. The journal is essential reading for all wound-care specialists - nurses, doctors and researchers -- who are keen to keep up-to-date with all developments in wound management and tissue viability, but also appeals to generalists wishing to enhance their practice. JWC is internationally renowned for its cutting edge and state-of-the-art research and practice articles. The
'/>"/>

SOURCE Derma Sciences
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
2. Data from Randomized Pilot Study, Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
3. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
4. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
5. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
6. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
7. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
10. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
11. Large Controlled Trial of Widely Used Mood Stabilizers Demonstrates Efficacy in Pediatric Bipolar Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... , May 26, 2015  MGC Diagnostics Corporation (NasdaqCM: MGCD), ... to discuss its financial results for the second quarter of ... at 4:30 p.m. ET on Tuesday, June 2, 2015. The ... fiscal 2015 at the close of the markets on Tuesday, ... 317-6789 or (412) 317-6789 to access the conference call, or ...
(Date:5/26/2015)... Boehringer Ingelheim today announced that the ... STIOLTO™ RESPIMAT ® (tiotropium bromide and olodaterol) ... long-term, once-daily maintenance treatment of airflow obstruction in ... chronic bronchitis and/or emphysema. STIOLTO RESPIMAT is not ... COPD. COPD, which includes chronic bronchitis ...
(Date:5/26/2015)... 2015 Mast Therapeutics, Inc. ... its molecular adhesion and sealant technology (MAST) platform ... heart failure, and arterial disease, today reported that ... extension study of vepoloxamer (MST-188) in sickle cell ... enroll patients who have completed the Company,s Phase ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2015 Financial Results on Tuesday, June 2, 2015 2FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 2FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 3FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 4FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 5FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 6FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 7FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 8FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 9FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 10FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 11FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 12FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD 13Mast Therapeutics Announces Initiation Of EPIC-E Study 2Mast Therapeutics Announces Initiation Of EPIC-E Study 3Mast Therapeutics Announces Initiation Of EPIC-E Study 4Mast Therapeutics Announces Initiation Of EPIC-E Study 5
... 15, 2011 Pharmaceutical companies are dramatically increasing ... meet the demands of a patient-empowered, data-driven, outcomes-focused ... alone, pharmaceutical company investment in smart phone apps, ... other programs increased 78%, as companies embrace a ...
... Unilife Corporation ("Unilife" or "Company") (Nasdaq: ... the three and six months ended December 31, 2010 (Fiscal ... Completed, on-schedule, the construction of a new ... staff now working out of the new facility ...
Cached Medicine Technology:Pharmaceutical Industry Rapidly Expanding Partnerships With New Entrants in Health Care Space, Ernst & Young Finds 2Pharmaceutical Industry Rapidly Expanding Partnerships With New Entrants in Health Care Space, Ernst & Young Finds 3Pharmaceutical Industry Rapidly Expanding Partnerships With New Entrants in Health Care Space, Ernst & Young Finds 4Pharmaceutical Industry Rapidly Expanding Partnerships With New Entrants in Health Care Space, Ernst & Young Finds 5Unilife Corporation Announces Financial Results For Fiscal Year 2011 Second Quarter 2Unilife Corporation Announces Financial Results For Fiscal Year 2011 Second Quarter 3Unilife Corporation Announces Financial Results For Fiscal Year 2011 Second Quarter 4Unilife Corporation Announces Financial Results For Fiscal Year 2011 Second Quarter 5Unilife Corporation Announces Financial Results For Fiscal Year 2011 Second Quarter 6Unilife Corporation Announces Financial Results For Fiscal Year 2011 Second Quarter 7
(Date:5/26/2015)... NC (PRWEB) May 26, 2015 ... compliance solutions for the health and human services market, ... to meet demand. After strong attendance and participation in ... groups, and give their annual user conference an exciting ... Relias customers to come together and discuss best practices, ...
(Date:5/26/2015)... May 26, 2015 Mr. Larry Westenberg ... expert in Neuro-Linguistic Programming, or NLP. Mr. Westenberg ... Rapid Resolution Therapy® or RRT®. While many people ... and applied it to specific areas, Mr. Westenberg has ... for over 20 years. He works with people ...
(Date:5/26/2015)... Santa Rosa, CA (PRWEB) May 26, 2015 ... Management and Analytics solutions for more than 15 years, ... from the National Committee for Quality Assurance (NCQA) for ... today. , “We are proud of the work we ... years and are grateful for the acknowledgement from NCQA ...
(Date:5/26/2015)... Pass, OR (PRWEB) May 26, 2015 ... always fatal if not caught early. Melanoma is also ... water advocate Sharon Kleyne, the melanoma rate is on ... radiation. While the melanoma risk for indoor tanning salon ... these establishments. The most recent ban, in Pennsylvania, coincides ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Writers ... Editor with the Vasont® CCMS to make creating, ... Systems, a top component content management system (CCMS) ... (VUI) extension supports oXygen XML Editor Version 17.0, ... Vasont Universal Integrator extension merges key editorial functionality ...
Breaking Medicine News(10 mins):Health News:Relias Learning Expands User Groups and Industry Influence 2Health News:Relias Learning Expands User Groups and Industry Influence 3Health News:i2iTracks Earns NCQA 2014 PCMH Prevalidation 2Health News:i2iTracks Earns NCQA 2014 PCMH Prevalidation 3Health News:Skin Cancer Awareness Month: Pennsylvania Ban of Teens from Tanning Salons Is Praised by Fresh Water Advocate Sharon Kleyne 2Health News:Skin Cancer Awareness Month: Pennsylvania Ban of Teens from Tanning Salons Is Praised by Fresh Water Advocate Sharon Kleyne 3Health News:Vasont Systems Certifies the Integration between the Vasont® Component Content Management System and oXygen® XML Editor 17.0 2
... changes and inflammation has been awarded a Wellcome Trust ... The research programme at the National Institute for Health ... Professor Julian Davis, a consultant endocrinologist at Manchester Royal ... Biomedicine Research Group. He is working with Professor ...
... the Walter and Eliza Hall Institute in Melbourne, Australia, has ... further research into an aggressive and highly lethal form of ... the cell lining (epithelium) of the ovary, accounts for 90 ... still poorly understood, and recent research has revealed that it ...
... TUESDAY, Oct. 26 (HealthDay News) -- New research challenges previous ... with a certain genetic mutation. While guidelines have recommended ... their KRAS gene should not receive the targeted ... of these patients might actually benefit from taking the drug. ...
... , TUESDAY, Oct. 26 (HealthDay News) -- ... physicians, and this may be one reason for U.S. ... new study. Researchers looked at the wages of ... them into four broad categories: primary care; surgery; internal ...
... School of Medicine and The Children,s Hospital have taken a ... serious liver diseases in infants. The disease is called ... through which bile, crucial for digestion, flows to the small ... one in 10,000 births. But it,s life-threatening. "It ...
... In the 15 minutes a primary care doctor typically ... ailment, help manage ongoing health issues and provide preventive care. ... immediate mental health needs of patients is an ongoing challenge. ... Michigan Health System, however, points to an encouraging strategy for ...
Cached Medicine News:Health News:Manchester team wins $1.9 million grant for 'cell control' study 2Health News:VCA fellowship funding to extend ovarian cancer research 2Health News:New Insights on Who Should Take Erbitux for Colon Cancer 2Health News:Primary Care MDs at Low End of Pay Scale, Study Finds 2Health News:Breakthrough in understanding life-threatening childhood liver disease 2Health News:Follow-ups prove powerful tool for treating depression in primary care 2
10 L, Bulk Recommended for 2, 5 and 10 L pipettes....
10 L, Bulk Recommended for 2, 5, 10 L pipettes....
... Theken eDISC is a revolutionary advancement in ... assess and manage their patients. The eDISC's ... the eDISC from 1st and 2nd generation ... loads of the lumbar spine, the eDISC ...
... Resistant Tips offer a safe alternative to ... designed for applications such as PCR(a), pipetting ... ART Tips are excellent for tissue culture, ... ART Tips prevent aerosol contaminants and liquids ...
Medicine Products: